secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001655759-24-000002
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas gets FDA/EMA clearance for ARV-393 and ARV-102; Phase 1 trials planned H1 2024
--------------------------------------------------------------------------------

- FDA authorized IND for ARV-393, a PROTAC BCL6 degrader.
- EMA authorized CTA for ARV-102, a PROTAC LRRK2 degrader.
- Both first-in-human Phase 1 trials expected to start in H1 2024.
- ARV-393 targets BCL6 protein; ARV-102 targets LRRK2 protein.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000002/0001655759-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000002/arvn-20240107.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer